Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
That’s why, according to FDA’s Oncology Center of Excellence, the determination of an appropriate endpoint in oncology is based on the specific disease and is highly dependent upon numerous factors. But unlike ORR, PFS is considered by FDA to be a more appropriate measure of stable disease and is thought to be correlated to overall survival.
40 
Let's personalize your content